

学位論文の要旨

氏名 三井 要造

- 学位論文名 Tumor Suppressor Function of PGP9.5 Is Associated with Epigenetic Regulation in Prostate Cancer - Novel Predictor of Biochemical Recurrence After Radical Surgery
- 発表雑誌名 Cancer Epidemiology Biomarkers and Prevention
(巻: 初頁～終頁等, 年) 21: 487-496, 2012
- 著者名 Yozo Mitsui, Hiroaki Shiina, Miho Hiraki, Naoko Arichi, Takeo Hiraoka, Masahiro Sumura, Sathoshi Honda, Hiroaki Yasumoto, Mikio Igawa

論文内容の要旨

INTRODUCTION

Protein Gene Product 9.5 (PGP9.5) is presumed to be a common antigen in both neuroendocrine (NE) and secretory cells in the prostate. In human solid tumors, the expression level of *PGP9.5* is frequently down-regulated because of promoter CpG hypermethylation, and in fact, *PGP9.5* has been considered as a tumor suppressor gene. Unfortunately, only a limited amount of information is available on *PGP9.5*, in regards to the human prostate glands, making it difficult to evaluate its functional role as a tumor-suppressant and its active involvement in NE differentiation.

The aim of the present study was to assess the correlation between expression of the *PGP9.5* gene and epigenetic mechanisms. In addition, we evaluated the associations between the expression of *PGP9.5* or CpG methylation of the PGP9.5 status and clinical parameters or biochemical recurrence (BCR) in cases of localized prostate cancer (PC) following a radical prostatectomy (RP).

MATERIALS AND METHODS

To screen for epigenetic alterations in the *PGP9.5* gene, prostate cancer cell lines of LNCaP (androgen-dependent) and PC-3 (androgen-independent) were treated with a de-methylating agent of 5-aza-2'-deoxycytidine (5-aza-dC) in duplicate. The difference in

expression level of the *PGP9.5* mRNA transcripts, before and after 5-aza-dC treatment, was analyzed by a quantitative RT-PCR using cDNA from these cell lines. To determine the functional role of the *PGP9.5* gene, methyl thiazolyl tetrazolium (MTT) and apoptosis assay were performed using LNCaP or PC-3 cells transfected with the *PGP9.5* gene's small interfering RNA (siRNA).

The promoter CpG hypermethylation and mRNA transcript level of *PGP9.5* gene was analyzed in prostate cancer cell lines—226 localized PC samples from radical prostatectomy cases, and 80 pathologically proven benign prostate hyperplasia (BPH) tissues. From these samples, genomic DNA, bisulfite-modified DNA, and cDNA were prepared. Both methylation specific and un-methylation specific primers were designed by a MethPrimer (<http://www.urogene.org/methprimer/>), and PCR was done using bisulfite-modified DNA as a template. For bisulfite DNA sequencing, a pair of universal primers, in which no CpG islands were present, was used to confirm the methylation status of each CpG island. The mRNA transcript level of the *PGP9.5* gene was measured by a quantitative RT-PCR using G3PDH as a reference gene.

Parametric data were statistically analyzed through an ANOVA test followed by a *post hoc* test. Non-parametric data were analyzed by a X-square test. The probability factor of BCR-free probability was estimated using the Kaplan-Meier method, and survival curves among groups were compared statistically using the log-rank test. An age-adjusted logistic regression model was applied to determine the independent factors contributing to the BCR. A P-value of less than 0.05 was considered as statistically significant.

RESULTS AND DISCUSSION

In this present study, we hypothesized that expression of *PGP9.5* in PC tissue is regulated by epigenetic alteration of CpG methylation and that the harboring of *PGP9.5* in PC functions as a tumor-suppressant. Irrespective of the androgen-dependent potential of PC cell lines used, a 5-aza-dC treatment significantly increased the mRNA transcript of *PGP9.5* when compared to the non-treatment of 5-aza-dC, suggesting the probability of CpG hypermethylation as a regulator of the *PGP9.5* gene expression in human PC cells. Bisulfite DNA sequencing of the *PGP9.5* promoter showed that complete methylation was found in PC3 cells, and partial, but not complete, methylation was dominant in LNCaP cells. This probably explains why the detectable level of *PGP9.5* mRNA transcript was found even before the 5-aza-dC treatment in LNCaP cells.

We found that the siRNA transfection of *PGP9.5* in LNCaP cells, in which partial methylation was found in the CpG promoter and wherein weak levels of mRNA transcript of *PGP9.5* was detected, significantly enhanced cell viability through the acceleration of the

inhibitory effect on cultured cells in spite of a significant lower amount of *PGP9.5* mRNA transcript in LNCaP. Furthermore, we found a significant difference in apoptotic cells between the *PGP9.5* siRNA transfection and the control siRNA transfection in LNCaP cells, which suggests the enhancement of the apoptosis after the *PGP9.5* siRNA transfection. On the contrary, in PC3 cells in which the *PGP9.5* mRNA transcript was not absolutely detectable due to complete methylation of the CpG promoter, the inhibitory effect of siRNA transfection of *PGP9.5* on cell viability of PC3 cells was not found. These findings strongly indicate the potential of *PGP9.5* as a tumor-suppressant in human PC tissues.

Subsequently, we investigated the prognostic relevance of *PGP9.5* methylation or *PGP9.5* expression, focusing on the probability of early detection of BCR after radical surgery. Univariate analysis showed that the lower BCR-free probability was significantly associated with higher *PGP9.5* expression or negative *PGP9.5* methylation. Age-adjusted multivariate analysis clearly demonstrated the prognostic relevance of *PGP9.5* methylation to predict an early BCR after surgery following the pT category. We also identified *PGP9.5* methylation as an independent factor superior to the Gleason score. In PC tissues, perineural invasion is supposed to be a substantial gateway for PC cells to spread out from the prostate. The perineural invasion of PC cells was found to be relevant to BCR after surgery showing significant correlation with *PGP9.5* methylation.

In general, a high Gleason score, high pT category, increased tumor volume, and positive surgical margins are all major concerns for BCR and might constitute independent factors for predicting BCR following RP; however, they do not always exactly predict BCR due to the biological variability of PC. In this study, we showed that further stratification with the pT category, in addition to methylation status, identified stepwise reduction of the BCR-free probability, in which the highest BCR-free probability was found in the PCs with both methylation-negative and a pT category of less than 2; and the lowest was in those PCs with methylation-positive and a pT category of more than 3a. Based on our data, we derived that CpG methylation of the *PGP9.5* status, in combination with a pathological T stage, and a more accurately predicted BCR, may help identify and select patients who should be submitted to additional treatment following RP.

CONCLUSION

The epigenetics of promoter CpG hypermethylation of *PGP9.5* may be one of the mechanisms associated with the down-regulation and functional loss of *PGP9.5* in human PC. We have concluded that CpG methylation of the *PGP9.5* status, in combination with a pathological T stage, can more accurately predict BCR, and may help to identify and narrow-down the selection of patients in need of additional treatment following RP.

氏名	三井 要造
学位の種類	博士（医学）
学位記番号	乙第298号
学位授与年月日	平成25年7月29日
審査委員	主査 教授 磯部 威
	副査 教授 並河 徹
	副査 教授 竹下 治男

論文審査の結果の要旨

人口の高齢化に伴って、前立腺癌は罹患率、死亡率ともに増加しており、より優れた診断法や、有効な治療法の開発が望まれている。Protein G product 9.5遺伝子(PGP9.5)は、ユビキチンカルボキシルターミナルヒドロラーゼとリガーゼの相反する機能を持つ神経特異的蛋白を発現し、これまで種々の癌腫においてがん抑制遺伝子として機能することが報告されてきた。また、その発現はプロモーター領域のDNAメチル化により調節されることも報告されており、消化器癌ではPGP9.5のメチル化が生物学的悪性度の評価に有用であることが示されている。局所進行前立腺癌は、術後に25%の症例が前立腺特異抗原(PSA: prostate specific antigen)再発(生化学的再発)を来すため、有用な再発予測因子の同定が必要である。本研究の目的は前立腺癌におけるPGP9.5の発現とメチル化の意義を明らかにし、PSA再発の予測因子としての評価を行うことである。研究者らはメチル化ヒト前立腺癌細胞株を用いて、まずPGP9.5の発現とプロモーター領域のDNAメチル化との関連および、PGP9.5の機能を評価した。次に前立腺全摘症例におけるPGP9.5のメチル化、発現量と臨床病理学的所見、術後PSA再発(生化学的再発)との相関を検討した。本研究は島根大学医学部医の倫理委員会で承認された臨床研究である。

前立腺癌培養細胞株における検討では、PGP9.5の発現はプロモーター領域のDNAメチル化により調節されており、PGP9.5 siRNA トランスフェクション後に細胞生存性の増加と、アポトーシスの低下が見られた。臨床検体を用いた検討では、PGP9.5のメチル化率は前立腺肥大症と比較し前立腺癌で高率であり、PGP9.5の発現は培養細胞株と同様にプロモーター領域のDNAメチル化により調節されていた。さらに、PGP9.5のメチル化およびその発現は前立腺癌の生物学的悪性度を反映し、PGP9.5のメチル化は局所進行前立腺癌における術後PSA再発と有意に相関した。

以上より、前立腺癌においてPGP9.5はがん抑制遺伝子として機能し、PGP9.5のメチル化の評価は術後PSA再発を予測する有用な分子マーカーになりうると思われる。

本研究はPGP9.5の前立腺癌における意義を明らかにしたものであり、学術的にも臨床的にも優れた成果である。